US Stock MarketDetailed Quotes

Enanta Pharmaceuticals (ENTA)

Watchlist
  • 13.455
  • -0.065-0.48%
Trading Aug 12 13:48 ET
391.25MMarket Cap-5.56P/E (TTM)

About Enanta Pharmaceuticals Company

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Company Profile

SymbolENTA
Company NameEnanta Pharmaceuticals
Listing DateMar 21, 2013
Issue Price14.00
ISINUS29251M1062
CEODr. Jay R. Luly, PhD
MarketNASDAQ
Employees120
Fiscal Year Ends09-30
Address4 Kingsbury Avenue
CityWatertown
ProvinceMassachusetts
CountryUnited States of America
Zip Code02472
Phone1-617-607-0800
Websitehttp://www.enanta.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Jay R. Luly, PhD
  • Director, President and Chief Executive Officer
  • 2.77M
  • Matthew P. Kowalsky
  • Chief Legal Officer and Corporate Secretary
  • --
  • Brendan Luu
  • Chief Business Officer
  • --
  • Dr. Yat Sun Or, PhD
  • Chief Scientific Officer
  • 1.29M
  • Dr. Tara Lynn Kieffer, PhD
  • Chief Product Strategy Officer
  • --
  • Dr. Scott T. Rottinghaus, M.D.
  • Chief Medical Officer
  • 1.34M
  • Kathleen S. Capps, C.P.A.
  • Executive Director, Accounting, Controller and Interim Principal Accounting Officer
  • --
  • Harry R. Trout, III
  • Vice President, Finance and Principal Financial Officer
  • --
  • Dr. Bruce L.A. Carter,PhD
  • Non-Executive Chairman of the Board
  • 158.83K
  • Kristine Peterson
  • Independent Director
  • 131.33K
  • Yujiro S. Hata
  • Independent Director
  • 123.83K
  • Terry C. Vance
  • Independent Director
  • 138.83K
  • Mark G. Foletta
  • Independent Director
  • 136.33K
  • Dr. Lesley Russell, M.R.C.P.,MB.Ch.B.
  • Independent Director
  • 126.33K
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +15.27%
Sample Name
Sample Code
 +8.61%
Sample Name
Sample Code
 +8.21%
4
United Sts Brent Oil Fd Lp Unit
BNO
+6.56%
5
United States Oil Fund LP
USO
+4.69%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +37.94%
Sample Name
Sample Code
 +7.82%
Sample Name
Sample Code
 +7.64%
4
Hesai
HSAI
+5.81%
5
Taiwan Semiconductor
TSM
+3.92%
View More
Middle East conflict spreads to the stock market! How should investors respond?
Ahead of the market open, US Treasury Secretary Bessent indicated that the United States and Iran are poised to reach an agreement the follo Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -